Theravance Biopharma, Inc. has announced its financial results for the second quarter of 2025, reporting a total revenue of $26.2 million. This includes $18.7 million from Viatris collaboration revenue and $7.5 million from licensing revenue following YUPELRI's regulatory approval in China. The Viatris collaboration revenue saw a significant increase of 31% compared to the same period in 2024, driven by the company's 35% share of YUPELRI net sales, which rose to $23.2 million, marking a 22% increase year-over-year. YUPELRI net sales, recorded by Viatris, reached $66.3 million, up 22% from the previous year. The company reported a net income of $54.8 million for the second quarter of 2025, a substantial improvement from a net loss of $16.5 million in the same period of 2024. Non-GAAP net loss from operations was reduced to $4.2 million from $6.3 million in the previous year. In terms of financial guidance, Theravance Biopharma expects full-year 2025 R&D expenses to range between $32 million and $38 million, and SG&A expenses to be between $50 million and $60 million, excluding share-based compensation. Share-based compensation expenses are projected to be between $18 million and $20 million for the year. The company completed the sale of its TRELEGY ELLIPTA royalty interest to GSK for $225 million and is on track to trigger a $50 million milestone for TRELEGY sales in 2025. With a strong balance sheet, Theravance Biopharma reports holding $338.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, and has no debt. The company continues to focus on completing enrollment in its pivotal Phase 3 CYPRESS study by late summer, with top-line data expected approximately six months later.